Switch theme
Sign up to access all valuation multiples
Galderma was formed in 1981 as a joint venture between Nestle and L’Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a standalone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma’s science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 45% of net sales from the US and employs around 6,600 people.
1981
n/a
LTM Revenue $3.9B
LTM EBITDA $902M
$39.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Galderma Group has a last 12-month revenue (LTM) of $3.9B and a last 12-month EBITDA of $902M.
In the most recent fiscal year, Galderma Group achieved revenue of $5.6B and an EBITDA of $1.2B.
Galderma Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Galderma Group valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.9B | XXX | $5.6B | XXX | XXX | XXX |
| Gross Profit | $2.7B | XXX | $3.9B | XXX | XXX | XXX |
| Gross Margin | 70% | XXX | 69% | XXX | XXX | XXX |
| EBITDA | $902M | XXX | $1.2B | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 22% | XXX | XXX | XXX |
| EBIT | $765M | XXX | $853M | XXX | XXX | XXX |
| EBIT Margin | 19% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $320M | XXX | $291M | XXX | XXX | XXX |
| Net Margin | 8% | XXX | 5% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $2.8B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 16, 2025, Galderma Group's stock price is CHF 126 (or $158).
Galderma Group has current market cap of CHF 29.8B (or $37.5B), and EV of CHF 31.7B (or $39.8B).
See Galderma Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $39.8B | $37.5B | XXX | XXX | XXX | XXX | $2.60 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 16, 2025, Galderma Group has market cap of $37.5B and EV of $39.8B.
Galderma Group's trades at 7.1x EV/Revenue multiple, and 33.0x EV/EBITDA.
Equity research analysts estimate Galderma Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Galderma Group has a P/E ratio of 93.2x.
See valuation multiples for Galderma Group and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $37.5B | XXX | $37.5B | XXX | XXX | XXX |
| EV (current) | $39.8B | XXX | $39.8B | XXX | XXX | XXX |
| EV/Revenue | 8.1x | XXX | 7.1x | XXX | XXX | XXX |
| EV/EBITDA | 35.1x | XXX | 33.0x | XXX | XXX | XXX |
| EV/EBIT | 41.4x | XXX | 46.7x | XXX | XXX | XXX |
| EV/Gross Profit | 11.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 93.2x | XXX | 129.1x | XXX | XXX | XXX |
| EV/FCF | 80.0x | XXX | 148.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGalderma Group's last 12 month revenue growth is 9%
Galderma Group's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Galderma Group's rule of 40 is 30% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Galderma Group's rule of X is 46% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Galderma Group and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 2% | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Growth | 14% | XXX | 2% | XXX | XXX | XXX |
| Rule of 40 | 30% | XXX | 31% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 46% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 34% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 54% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Acme United | XXX | XXX | XXX | XXX | XXX | XXX |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Live Verdure | XXX | XXX | XXX | XXX | XXX | XXX |
| Lavipharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Sarantis Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Galderma Group acquired XXX companies to date.
Last acquisition by Galderma Group was XXXXXXXX, XXXXX XXXXX XXXXXX . Galderma Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Galderma Group founded? | Galderma Group was founded in 1981. |
| Where is Galderma Group headquartered? | Galderma Group is headquartered in Switzerland. |
| Is Galderma Group publicy listed? | Yes, Galderma Group is a public company listed on SWX. |
| What is the stock symbol of Galderma Group? | Galderma Group trades under GALD ticker. |
| When did Galderma Group go public? | Galderma Group went public in 2024. |
| Who are competitors of Galderma Group? | Similar companies to Galderma Group include e.g. Acme United, EZZ Life Science, Live Verdure, Lavipharm. |
| What is the current market cap of Galderma Group? | Galderma Group's current market cap is $37.5B |
| What is the current revenue of Galderma Group? | Galderma Group's last 12 months revenue is $3.9B. |
| What is the current revenue growth of Galderma Group? | Galderma Group revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Galderma Group? | Current revenue multiple of Galderma Group is 8.1x. |
| Is Galderma Group profitable? | Yes, Galderma Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Galderma Group? | Galderma Group's last 12 months EBITDA is $902M. |
| What is Galderma Group's EBITDA margin? | Galderma Group's last 12 months EBITDA margin is 23%. |
| What is the current EV/EBITDA multiple of Galderma Group? | Current EBITDA multiple of Galderma Group is 35.1x. |
| What is the current FCF of Galderma Group? | Galderma Group's last 12 months FCF is $396M. |
| What is Galderma Group's FCF margin? | Galderma Group's last 12 months FCF margin is 10%. |
| What is the current EV/FCF multiple of Galderma Group? | Current FCF multiple of Galderma Group is 80.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
